Concepedia

Author

M. Fukuoka

Kindai UniversityORCID

Also Known As

H Niitani, M Fukuoka, M. Fukuoka, Maki Fukuoka, Miyu Fukuoka, N Masuda, N Yamamoto, T Komiya

180

Publications

5.7K

Citations

38

H-Index

79

Concepts

All Affiliations

Kindai UniversityNational Cancer Center Hospital EastOsaka City General HospitalOsaka Prefectural Medical CenterOsaka City University
MF

About

M. Fukuoka is an author at Kindai University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

49

2.1K

2

Health Sciences

15

20

704

3

Public Health

3

3

150

4

Allergy

1

1

20

5

Allergy Medicine

1

1

20

M. Fukuoka

×

72

Publications

4.7K

Citations

36

H-Index

YearCitations

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Yuichiro Ohe, Yasuo Ohashi, Kaoru Kubota,

Annals of Oncology

2006

635

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

M. Fukuoka, H Niitani, Atsushi Suzuki,

Journal of Clinical Oncology

1992

434

A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group.

Kiyoyuki Furuse, M. Fukuoka, H. Kato,

Journal of Clinical Oncology

1993

283

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Kazuhiko Nakagawa, Tomohiro Tamura, Shunichi Negoro,

Annals of Oncology

2003

274

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Kenji Tamura, Isamu Okamoto, Tatsuhiko Kashii,

British Journal of Cancer

2008

203

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.

Satoshi Kudoh, Yasuhiro Fujiwara, Y Takada,

Journal of Clinical Oncology

1998

170

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.

N Masuda, M. Fukuoka, M Takada,

Journal of Clinical Oncology

1992

141

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Nobuyuki Yamamoto, Takashi Seto, Makoto Nishio,

Lung Cancer

2020

122

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)

M. Fukuoka, Yi‐Cheng Wu, S. Thongprasert,

Journal of Clinical Oncology

2009

119

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

Yusaku Akashi, Isamu Okamoto, Tsutomu Iwasa,

British Journal of Cancer

2008

101

Page 1